Haleon (HLN) EPS (Basic) (2021 - 2023)

Haleon (HLN) posted EPS (Basic) of $0.09 for Q4 2023, up 128.68% on a QoQ basis from $0.04 in Q2 2023, and down 15.65% year-over-year from $0.11 in Q4 2022.

Haleon (HLN) EPS (Basic) (2021 - 2023) Analysis & Trends

Haleon's EPS (Basic) history runs 3 years deep, the most recent figure standing at $0.09 for Q4 2023.

  • Quarterly EPS (Basic) fell 15.65% year-over-year to $0.09 in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $0.09 (down 29.27% YoY) and the FY2025 annual result came in at $0.24, up 21.23% from the prior year.
  • EPS (Basic) was $0.09 for Q4 2023 at Haleon, up from $0.04 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.13 in Q4 2021 and bottomed at $0.04 in Q2 2023.
  • A 3-year average of $0.09 and a median of $0.1 in 2023 frame the typical range for EPS (Basic).
  • Annual changes were most pronounced in 2022 — EPS (Basic) slipped 12.99% — and 2023, when it dropped 15.65%.
  • Haleon's EPS (Basic) stood at $0.13 in 2021, then retreated by 12.99% to $0.11 in 2022, then declined by 15.65% to $0.09 in 2023.
  • Business Quant data shows HLN's EPS (Basic) at $0.09 in Q4 2023, $0.04 in Q2 2023, and $0.05 in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Basic) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 0.32
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 1.42
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -1.49
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.32
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 0.15
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.97
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 0.11
10 Vireo Growth 10.57 Bn 10.41 Bn 59.30 Mn -0.02

Historic Data

Download Data
DateValue
Dec 31, 2023 0.09
Jun 30, 2023 0.04
May 3, 2023 0.05
Dec 31, 2022 0.11
Sep 20, 2022 0.11
Dec 31, 2021 0.13